Good Showing For Nycomed's COPD Drug Daxas
This article was originally published in The Pink Sheet Daily
Executive Summary
Reports in the Aug. 27 Lancet look good for the novel phosphodiesterase-4 inhibitor, under consideration by U.S. and EU regulators.
You may also be interested in...
Daxas Advisory Committee Review May Look At Inclusion Criteria For Pivotal Trials
Forest's oral COPD drug will go before FDA's Pulmonary-Allergy Drugs Advisory Committee on April 7.
Daxas Advisory Committee Review May Look At Inclusion Criteria For Pivotal Trials
Forest's oral COPD drug will go before FDA's Pulmonary-Allergy Drugs Advisory Committee on April 7.
For Forest, No Single Silver Bullet But Many Opportunities
There is no quick fix to guide Forest Laboratories through 2012, when its best-seller, the antidepressant Lexapro, goes off patent. But management thinks it will have enough patches in place by then to compensate for lost revenues and avert disaster